Nes-Ziona, Israel, Sept. 6, 2022 (GLOBE NEWSWIRE) — Enlivex Therapeutics Ltd. ENLV the “Company”))), a clinical-stage macrophage reprogramming immunotherapy company targeting diseased macrophages in patients with sepsis and solid tumors, announced today that the U.S. Patent and Trademark Office has received a statement of approval for the Patent Application No. 15/551,284. Once granted, the resulting patent will grant Enlivex additional intellectual property (IP) protection through at least 2036 with claims covering methods of using Allocetra™ to inhibit or reduce cytokine release syndrome in patients undergoing a T cell -Undergoing chimeric antigen receptor (CAR) therapy. The Company expects this new patent to be issued in the United States by the end of Q1 2023.

Oren Hershkovitz, PhD, CEO of Enlivex, commented, “We look forward to the anticipated issuance of this patent, which will expand the robust IP portfolio protecting Allocetra™ and our various development programs. This IP portfolio is an important source of value for Enlivex and we remain committed to its preservation and continued expansion.”

CAR-T cells are T cells that have been genetically engineered to contain a receptor that allows them to target and destroy cancer cells. While several CAR-T cell treatments have recently been approved by the FDA for multiple cancer indications, in many patients such treatments have been associated with a side effect called cytokine release syndrome, which describes a cluster of potentially serious or life-threatening symptoms that occur due to overactivation of immune pathways . Preclinical data indicate that Allocetra™ has the potential to prevent or reduce cytokine release syndrome associated with CAR-T cell therapies.

ABOUT ALLOCETRA™
Allocetra™ is being developed as a universal, ready-to-use cell therapy to reprogram macrophages to their homeostatic state. Diseases like solid cancer, sepsis and many others reprogram macrophages…